Budget impact analysis of revumenib for the treatment of relapsed or refractory acute leukemias with a KMT2A translocation in the United States

Abraham I, et al.

Citation

J Manag Care Spec Pharm. 2025 Jul;31(7):680-693.

PMID

40459635